Overview

The Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HC022 Injection in Subjects With SLE/CLE

Status:
NOT_YET_RECRUITING
Trial end date:
2027-09-24
Target enrollment:
Participant gender:
Summary
The primary objective of this phase Ib study is to evaluate the safety and tolerability of multiple-ascending, subcutaneous (SC) doses of HC022 in SLE/CLE subjects. Secondary objectives of study are as follows: To estimate the PK parameters of multiple-ascending SC doses of HC022 in SLE/CLE subjectsTo evaluate the immunogenicity of HC022 administered to SLE/CLE subjects.
Phase:
PHASE1
Details
Lead Sponsor:
HC Biopharma Inc.